KLS-13019

N/A

Report date: 2024/05/15 15:12:45
NMEFirst In Class

Base Information

Drug NameKLS-13019
Drug Alias NameKLS-13019
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonistsCannabinoid CB2 receptor inverse agonists
TargetsCannabinoid CB1 receptorCannabinoid CB2 receptor
Therapy Area/IndicationsPeripheral Nervous System DiseasesHepatic Encephalopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKannalife Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Neurological Disorders And StrokeNeuropathix Inc
Inactive CompaniesN/A
Active IndicationsPeripheral Nervous System Diseases
Inactive IndicationsHepatic Encephalopathy

Other Information

ATC CodeN/A
Related LinksWikipedia